In the BioHarmony Drug Report Database
Orladeyo (berotralstat) is a small molecule pharmaceutical. Berotralstat was first approved as Orladeyo on 2020-12-03. It has been approved in Europe to treat hereditary angioedemas. It is known to target plasma kallikrein. Orladeyo’s patents are valid until 2039-11-01 (FDA).
Image (chem structure or protein)